ABIVAX Société Anonyme (NASDAQ:ABVX) Given Market Outperform Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a research report released on Friday,Benzinga reports. They currently have a $33.00 target price on the stock.

Separately, Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $38.67.

ABIVAX Société Anonyme Stock Performance

Shares of ABIVAX Société Anonyme stock opened at $6.38 on Friday. ABIVAX Société Anonyme has a 1-year low of $6.26 and a 1-year high of $17.02. The business has a 50-day moving average of $8.38 and a 200-day moving average of $10.46.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several large investors have recently added to or reduced their stakes in the company. abrdn plc raised its holdings in shares of ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares during the period. Point72 Asset Management L.P. grew its position in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares during the last quarter. Walleye Capital LLC raised its stake in ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after acquiring an additional 80,807 shares during the period. BNP Paribas Financial Markets lifted its holdings in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new position in ABIVAX Société Anonyme in the fourth quarter valued at approximately $29,000. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.